High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma

High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastomaHigh-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma, Published online: 19 April 2018; doi:10.1038/s41409-018-0159-8High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma

Source: Bone Marrow Transplantation - April 19, 2018 Category: Hematology Authors: Sonata Jodele Christopher E. Dandoy Kasiani Myers Gregory Wallace Adam Lane Ashley Teusink-Cross Brian Weiss Stella M. Davies Source Type: research